Hormone Replacement in Young Women With Premature Ovarian Failure
Completed · Phase 2
Conditions studied: Healthy, Osteoporosis, Premature Ovarian Failure
In brief
The human ovary produces male sex hormones (androgen) and female sex hormones (estrogen). Currently, androgen is not included in hormone replacement therapy for women with premature ovarian failure. Present hormone replacement therapy (HRT) was designed to treat women who experience ovarian failure at menopause (around the age of 50). However, 1% of women will experience premature failure of the ovaries before the age of 40. There have been no studies conducted to determine proper hormone replacement therapies for these younger women. Some research suggests that the usual menopausal hormone replacement therapy is not adequate to protect young women with premature ovarian failure from developing osteoporosis. Women with premature ovarian failure have abnormally low levels of androgens circulating in their blood. This may contribute to the increase risk for osteoporosis. This study will compare two treatment plans for women with premature ovarian failure. Treatment plan one will be physiological estrogen hormone replacement. Treatment plan two will be physiological estrogen hormone replacement plus androgen. The study will attempt to determine which plan is more beneficial to women in relation to osteoporosis and heart disease. The hormones will be contained in patches and given by placing the patches against the patient's skin. The patches were designed to deliver the same amount of hormone as would be normally produced by the ovary in young women. The success of the treatment will be measured by periodically checking the density of patient's bone in the leg (femoral neck bone) . Researchers will take an initial (baseline) measurement of bone density before beginning treatment and then once a year, for 3 additional years, during treatment. The study will also consider bone density of the spine, bone turnover, heart disease risk factors, and psychological state.
Key facts
- Study ID
- NCT00001951
- Run by
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- People needed
- 250
- Starts
- 1999-12-01
- Expected to finish
- 2006-10-01
- Last updated by the study team
- 2007-02-27
Who can join
Age: 18 and older, up to 32. Sex: female. Healthy volunteers: accepted.
You may not qualify if…
- General:
- Smokers (more than 2 cigarettes per day).
- Alcohol users (more than 2 drinks of alcohol per day).
- Body mass index (BMI, kg/m(2)) greater than or equal to 30 and less than or equal to 19.
- Previous history of hip fracture or other active hip pathology.
- Abnormalities of the hip precluding the assessment of bone mineral density.
- Major dermatologic disorders, or a history of skin sensitivity to adhesive bandages, tape or transdermal matrix patches.
- Hirsutism score greater than 8.
- Acne score greater than 1.
- Hysterectomy
- Baseline free testosterone (FT) levels above the normal range (greater than 6.3 pg/ml in our current essay) and/or SHBG levels less than 36 nmol/L.
- Medical use:
- Any prior treatment in the past 6 months known to affect bone other than estrogen (i.e., calcitonin, biphosphonates, fluoride, anabolic steroids, testosterone, or herbal therapy that contains androstenedione, and DHEA).
- Current and/or past use of: diuretics, anticoagulants (heparin, Coumadin), glucocorticoid drugs, gonadotropin-releasing hormone agonist or antagonist therapy, chemotherapy.
- Medical history of:
- Anorexia nervosa, hyperprolactinemia, insulin-dependent diabetes, Cushing's syndrome, gastrectomy, osteogenesis imperfecta, mastocytosis, rheumatoid arthritis, long-term parenteral nutrition, hemolytic anemia, hemochromatosis and thalassemia, ankylosing spondylitis, multiple myeloma, Vitamin D deficiency, Paget's disease, primary hyperparathyroidism, hyperthyroidism, hypothyroidism, any cancer or any other major illness.
- Contraindications to hormone replacement therapy:
- Thromboembolic event associated with previous estrogen use History of endometrial cancer or hyperplasia
- History of breast cancer
- Hypertriglyceridemia (fasting triglyceride levels greater than 500 mg/dL)
- LDL greater than 190mg/dl
- Patients taking "statins"
- Serum Alkaline phosphatase greater than or equal to 2X the upper limit of normal
- Serum GGT greather than or equal to 2X the upper limit of normal
- Abnormal values on two or more hepatic panel tests
Where it is running
- National Institute of Child Health and Human Development (NICHD) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.